If our hypothesis is confirmed by further studies, a new targeted therapy and early medical intervention for YAP/TAZ could be a useful option for a subgroup of breast cancer cases complicated with LKB1 deficient, which may have important clinical and health implication. Here, YAP1 is linked to breast carcinoma.